Call us free on 0800 862 0373

Sign in to view your quotes
Email address:
Password or PIN:

Forgotten your password? Reset it here.

Ground-breaking new breast cancer drug shows promise in US trials

Published on 06/12/2012

A “ground-breaking” new drug has stopped the progression of an incurable form of breast cancer for more than two years in a US study.

The experimental breast cancer drug, called PD-0332991, is a new type of drug that works by blocking a protein critical in the cancer cell cycle.

The latest study involved 165 patients with the most common type of breast cancer whose tumours are oestrogen receptor-positive. All the participants had a metastatic form of the disease, meaning their cancer was no longer considered curable.

In the trial, patients were given PD-0332991 along with another drug called Femara. The findings showed no tumour progression for a median of 26.1 months, compared with 7.5 months in those who received Femara alone.

45 per cent of patients given the drug responded to therapy compared with 31 per cent given Femara. But when the researchers included women who had a stable form of the disease for six months or more, 70 per cent given both drugs benefitted compared with 44 per on Femara.

Side effects included low levels of white-blood cells, anaemia and fatigue. Lead researcher Richard Finns said:

"The magnitude of this benefit I don't think should be underestimated."

“These are patients who have incurable breast cancer. A lot of drugs in oncology have been approved or are getting a lot of traction because of improvements that last weeks to a few months. We have gone from 7 months to 26 months. That's ground-breaking."

These results were from the second of three stages of testing normally needed for approval in the U.S. Drug manufacturer Pfizer is moving the drug into the final stage of testing as quickly as possible with an international trial starting in 2013.

PD-0332991 will have to be awarded a European license before it is made available for prescription in the UK. But once it has been licensed and marketed, private health insurance patients could have access to it through their policy.

All new drugs have to be further approved by the National Institute for Health and Clinical Excellence (NICE) before being made widely available on the NHS, a process that usually takes a year or more.

© ActiveQuote Ltd. 2012


Categories:  Medical
Ground-breaking new breast cancer drug shows promise in US trialsA “ground-breaking” new drug has stopped the progression of an incurable form of breast cancer for more than two years in a US s    tweet it on twittershare with your friends on Facebookshare with your friends on MySpaceBlog it on your LinkedIn profile
 

No.1 health insurance broker as rated by customers

A great service from the initial call, to finalising the agreement. I would highly recommend to my family and friends.

Review centre member

Proactive, efficient, and offered me insurance I need. I would say half price I would end up paying if I did it by myself. Many thanks.

Review centre member

Excellent service. Explained everything in detail and really helped to find the right insurance best suited to my needs - which wasn't necessarily the most expensive. 

Review centre member

Good value and the advisor was very helpful and recommended the best policy for my grandson. I would definitely use this service again and recommend to others.

Review centre member

We were contacted in good time to make a knowledgable choice. We were given plenty of options with lots of information to enable us to make the right choice.

Review centre member

The service I received was excellent, the staff member was very efficient and knowledgable. She went out of her way to get the best policy for me.

Review centre member

Great service. I really appreciated the help provided by Active Quote to arrange health insurance. The agent was very informative and proactive. Many thanks!

Review centre member

I received excellent care and attention from the first phone call till the last. Friendly, efficient and patient.

Review centre member

Staff are very helpful, friendly and polite. They call back when they say they will and keep you up to date with progress. Pleasure to deal with.

Review centre member

Very polite and friendly, and gave detailed explanations of all aspects of the cover. Reassuring to know that if you do have a problem there is someone you can contact.

Review centre member
 
This site is operated by Insurance Broker ActiveQuote Ltd registered in England & Wales company number 6765845.
Authorised and Regulated by the Financial Conduct Authority (FCA). Firm reference number 501109 as detailed on the Financial Services Register. Please read our Key Facts document.
For information about your rights as a consumer visit Citizens Advice.

Our insurance comparison service is free and easy for you to use, but you are responsible for making sure all your information is entered correctly, and for choosing your insurer.

This site uses cookies in order to work correctly - these are not harmful and do not contain personal information. By using this site you consent to this. I understand  Tell me more

please wait ...